Background Recent retrospective data suggest that neoadjuvant androgen deprivation
therapy can improve the prognosis of high-risk prostate cancer (PCa) patients. Novel …

Background High-risk prostate cancer (PCa) patients have a high risk of biochemical
recurrence and metastatic progression following radical prostatectomy (RP). Objective To …

Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa)
remains uncertain. The primary endpoints of previous retrospective and phase II clinical …

Patients with high-risk prostate cancer treated with curative intent are at an increased risk of
biochemical recurrence, metastatic progression and cancer-related death compared with …

Background High-risk prostate cancer (PCa) patients frequently experience recurrence and
progression after radical prostatectomy (RP). Neoadjuvant androgen deprivation therapy …

5077 Background: GVAX-Prostate is a GM-CSF–secreting allogeneic cellular vaccine,
whose immunogenicity may be enhanced by androgen ablation as well as low-dose Cy. We …

Objective Treatment efficacy of androgen deprivation therapy with radical prostatectomy for
intermediate-to high-risk prostate cancer is less well-studied. The NEAR trial is a single-arm …

Purpose Cure rates for localized high-risk prostate cancers (PCa) and some intermediate-
risk PCa are frequently suboptimal with local therapy. Outcomes are improved by …

(1) Background: Several phase II studies, including randomized controlled trials (RCTs),
assessed the efficacy of adding androgen receptor signaling inhibitors (ARSIs) to androgen …

Purpose: Degarelix, a new gonadotropin-releasing hormone (GnRH) receptor antagonist
with demonstrated efficacy as first-line treatment in the management of high-risk prostate …